Latest News

Ruxolitinib can shape myelofibrosis care, and other drugs' dosing, resistance, and next-generation combinations are under study.

Phase 2 trial finds combination therapy resulted in 22% body weight reduction at 72 weeks, with 92% of weight loss attributable to fat mass, addressing concerns about muscle loss with GLP-1 receptor agonists.

Stable HCV E1E2 proteins on self-assembling nanoparticles spark strong mouse antibodies, advancing a long-sought hepatitis C vaccine.

Data from a phase 2 response-adapted trial identifies CD38 expression, plasma cell phenotype, and immune microenvironment as critical determinants of single-agent daratumumab efficacy.

Pharmacists are trusted experts in medication management and clinical care who bring essential clinical expertise to PBM reform efforts.

Sibeprenlimab, a new APRIL blocker, cuts proteinuria in IgA nephropathy.

Andrew Shao, PhD, senior vice president for global regulatory and scientific affairs at Niagen Bioscience, discusses how increased consumer access to information has shifted the supplement landscape toward greater demand for clinically validated products and transparency. He highlights the critical role pharmacists play in guiding consumers toward evidence-based supplements, while emphasizing the need for stronger regulatory enforcement and industry accountability to improve trust and product quality.

MS requires interdisciplinary collaboration, including pharmacists who can support patients throughout disease management.

A preclinical mucosal C difficile vaccine clears spores and prevents recurrence in animals, hinting at new protection for high‑risk patients.

The approval is significant for a condition that is estimated to affect fewer than 1 in 1 million individuals.

A 4-day course of a mycelium-based supplement reduced reactogenicity and sustained antibody levels for up to 6 months in COVID-naive participants.

Evolving myeloma therapies and pharmacist-led care reshape outcomes, tackling resistance, toxicity, and personalized treatment sequencing.

It’s been building for quite a while, but the dam seems to be breaking, and the 2 themes seem to be transparency and fiduciary duty.

OTC naloxone nasal sprays expand overdose rescue; pharmacists guide proper use, tackle stigma, and help communities curb opioid deaths.

A large observational study identifies U-shaped relationship between weekday sleep duration and estimated glucose disposal rate.

Ipsen discontinues tazemetostat after SYMPHONY-1 safety signals; pharmacists and FDA guide next steps for EZH2-mutant follicular lymphoma patients.

Adherence to glucose-lowering drugs ranges from 41% to 68% depending on drug class.

Early detection and prevention reduce risks of diverse adverse drug reactions.

Look‑alike, soundalike drugs increase errors, but systems can prevent them.

The FDA approves Bristol Myers Squibb’s deucravacitinib (Sotyktu), a first oral tyrosine kinase 2 inhibitor for active psoriatic arthritis.

Pharmacists quietly prevent medication harm, ease discharge chaos, and manage rising health care strain through unseen cognitive work.